Balance Sheet
Cash Flow Statement
AmortizationAmortization of Deferred ChargesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Depreciation & Amortization (CF) (2023 - 2025)

Historic Depreciation & Amortization (CF) for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $119000.0.

  • BioLineRx's Depreciation & Amortization (CF) fell 8583.33% to $119000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year decrease of 2079.48%. This contributed to the annual value of $4.1 million for FY2024, which is 19371.39% up from last year.
  • Latest data reveals that BioLineRx reported Depreciation & Amortization (CF) of $119000.0 as of Q3 2025, which was down 8583.33% from $176000.0 recorded in Q2 2025.
  • Over the past 5 years, BioLineRx's Depreciation & Amortization (CF) peaked at $1.9 million during Q4 2024, and registered a low of $119000.0 during Q3 2025.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $259000.0 (2023), whereas its average is $537181.8.
  • As far as peak fluctuations go, BioLineRx's Depreciation & Amortization (CF) skyrocketed by 28009.05% in 2024, and later plummeted by 8583.33% in 2025.
  • Over the past 3 years, BioLineRx's Depreciation & Amortization (CF) (Quarter) stood at $706000.0 in 2023, then surged by 162.32% to $1.9 million in 2024, then plummeted by 93.57% to $119000.0 in 2025.
  • Its last three reported values are $119000.0 in Q3 2025, $176000.0 for Q2 2025, and $165000.0 during Q1 2025.